AstraZeneca and CSPC Pharma Establish JV in Shijiazhuang: A New Paradigm for MNC Manufacturing in China

Aug 06, 2026 20:00 CST Updated 20:00

AstraZeneca

Pharmaceutical Technology Research and Development Provider

CSPC

Innovative Drug Research and Development, Manufacturer

A British pharmaceutical giant has decided to build its most advanced production line in a second-tier city on the North China Plain.

On August 5, AstraZeneca and CSPC signed an agreement to establish a joint venture company, building a next-generation biopharmaceutical production base in Shijiazhuang to further deepen their strategic cooperation.

The news was not unexpected.On the same day, CSPC announced that it had received a $10 million milestone payment from AstraZeneca—the fruit of an AI-driven drug development agreement signed by both parties in 2025. Subsequently, a deeper-level contract was brought to the forefront.

This is by no means a simple licensing deal. It is a joint venture, with CSPC holding a 51% stake and AstraZeneca holding a 49% stake.

From “selling products” to “licensing technology,” and further to “jointly building manufacturing facilities,” the relationship between CSPC and AstraZeneca has achieved a three-stage leap in less than two years. Behind this evolving partnership lies a profound transformation underway in China’s pharmaceutical industry: multinational pharmaceutical companies no longer view China merely as a sales market, and Chinese pharmaceutical firms are no longer content with serving solely as contract manufacturers.

TONACEA

More Than Just Building a Factory

The specific terms of this cooperation agreement appear straightforward.

The joint venture established by CSPC and AstraZeneca will initially focus on the production and supply of agreed-upon biologic drug substances for the global market.（DS）, to meet future production capacity expansion and commercial demands, the product portfolio may be further expanded.

However, beneath the literal terms of this agreement, there are several noteworthy aspects worth exploring in depth.

Key Point 1: Who Is Leading?

51% to 49%, with CSPC holding the controlling stake. This is uncommon for a top-ranked global multinational pharmaceutical company. Typically, in joint ventures established by MNCs in China, the foreign partner tends to hold a controlling interest or at least an equal share. This time, however, AstraZeneca has accepted the role of a minority shareholder.

This means that AstraZeneca has recognized CSPC’s capabilities in production and operations, and is even willing to integrate its global supply chain system into a manufacturing facility led by CSPC.

CSPC stated outright in its announcement that this collaboration “fully demonstrates the high recognition by a leading global multinational pharmaceutical company of its modernized production system, quality management capabilities, and industrialization execution capabilities.” Entrusting production capacity to your factory is, in itself, a vote of confidence with an extremely high threshold.

Second Highlight: AI-Driven GMP.

A key term in the positioning of the joint venture is “AI-driven GMP manufacturing operations.” CSPC’s investments in intelligent production in recent years are becoming one of its core assets for attracting international partners.

Traditional GMP relies on manual, person-to-person process management, whereas AI-driven GMP signifies that numerous steps, from production scheduling to quality control, can be optimized and monitored in real time by algorithms. This capability is precisely the “next-generation manufacturing capability” that AstraZeneca is seeking in its global supply chain layout.

Third Highlight: Globalized Production and Supply.

The joint venture’s products are not only supplied to the Chinese market but are also “produced and supplied for the global market.” This means that the biologics manufactured at the Shijiazhuang-based facility will directly enter AstraZeneca’s global supply chain in the future. China is not merely a sales market and R&D hub for AstraZeneca; it is increasingly becoming one of its global manufacturing hubs.

Highlight #4: This Is Just the Beginning.

The agreement also revealed that, with business development, capacity expansion, and growing commercial demands, both parties will further explore incorporating additional products into the joint venture’s operational scope in the future.

In other words, the “products agreed upon by both parties” currently stipulated serve merely as a starting point. The production capacity and product portfolio of this facility may expand significantly in the future as the collaboration deepens.

This joint venture also represents a key component of AstraZeneca’s commitment to invest RMB 100 billion in China by 2030. In January 2026, AstraZeneca announced its plan to invest over RMB 100 billion in China by 2030, comprehensively deepening its full-value-chain layout across R&D, manufacturing, commercialization, and ecosystem partnerships. The joint venture signing on August 5 marks a substantive implementation of this RMB 100 billion commitment on the manufacturing front.

TONACEA

From 5.3 Billion to 27.6 Billion

The Relationship Between CSPC and AstraZeneca: Four Major Collaborations in Less Than Two Years—Describing It as a “Whirlwind Romance” Is No Exaggeration.

First time: October 2024, initial foray into small molecules.

The initial collaboration between the two parties is a relatively traditional product licensing deal. AstraZeneca has secured exclusive global rights to YS2302018, a preclinical small-molecule drug from CSPC. CSPC received a $100 million upfront payment and is eligible for up to $370 million in development milestones and up to $1.55 billion in sales milestones, bringing the potential total value to approximately $1.92 billion. This represents a typical “product going global” scenario—CSPC sells a molecule, and AstraZeneca buys it.

Second: In June 2025, the AI platform debuted.

This collaboration has been upgraded, shifting from a single-product deal to jointly advancing the development of novel oral drug candidates by leveraging CSPC’s AI-driven drug discovery platform. CSPC received an upfront payment of $110 million, with a potential total value reaching $5.33 billion. Multinational corporations (MNCs) are beginning to pay for Chinese technological platforms—a significant signal.

Third time: January 2026, a "sky-high-priced deal" worth $18.5 billion.

This marks the largest outbound licensing deal by a Chinese pharmaceutical company to date. The two parties have signed an R&D collaboration and licensing agreement to jointly develop projects including SYH2082, a long-acting GLP-1R/GIPR agonist. The upfront payment amounts to $1.2 billion, with the total potential transaction value reaching $18.5 billion. GLP-1 is currently one of the most sought-after therapeutic areas globally. AstraZeneca’s willingness to pay such a high price for this asset from CSPC demonstrates that CSPC has accumulated global competitiveness in the field of peptide therapeutics.

Fourth: July 2026, Output from the Oligonucleotide Platform.

Just one month before the joint venture signing, the two parties further deepened their collaboration. This time, the partnership is anchored on CSPC’s proprietary siRNA drug discovery platform and its extrahepatic targeted delivery platform. The total potential deal value amounts to $1.77 billion. This marks a shift in the global expansion of Chinese oligonucleotide companies, upgrading from “single-product monetization” to “platform value export.”

Four Collaborations, with a Total Value Reaching $27.62 Billion: From Single-Product Licensing to AI Platform Partnerships, Blockbuster GLP-1 Deals, Oligonucleotide Platform Out-licensing, and Joint Venture Manufacturing—Each Marking a Strategic Upgrade

On the same day as the joint venture signing, CSPC also received a $10 million milestone payment from AstraZeneca, marking the fulfillment of deliverables under the AI drug collaboration agreement signed in June 2025.

The signing of the joint venture and the receipt of payment, when viewed together, send a crystal-clear signal: trust between the two parties has evolved from a “transactional relationship” to a “strategic symbiotic relationship.”

TONACEA

Why Now?

Only by placing the collaboration between CSPC and AstraZeneca within a broader coordinate system can one truly grasp the significance of this development.

First, the “BD explosion” of China’s innovative drugs.

In 2026, the momentum of outbound licensing for Chinese innovative drugs reached an unprecedented height. In the first half of the year, the total value of business development (BD) deals for Chinese innovative drugs amounted to $106.3 billion, approaching the full-year level of 2025. In the first quarter of 2026, the total value of cross-border licensing transactions reached $60 billion, representing a 73% year-on-year increase. Throughout 2025, there were 157 outbound licensing deals for Chinese innovative drugs, with a total value of approximately $135.7 billion, marking a significant surge from the 94 deals valued at $51.9 billion in 2024.

Multinational pharmaceutical companies are “scouring” China for deals. Eli Lilly, Pfizer, AstraZeneca… nearly every top-ranked global pharmaceutical giant has established dedicated business development (BD) teams in China to closely monitor the country’s early-stage R&D pipelines.

Secondly, the evolution of cooperation models: from "transactional" to "symbiotic."

In the past, collaboration between Chinese pharmaceutical companies and multinational corporations (MNCs) followed a relatively singular model: a Chinese company would develop a molecular entity and sell it to an MNC in exchange for an upfront payment and milestone payments, thereby concluding the transaction. This approach amounted to a “one-off deal.”

But now, the model is changing. Collaboration is shifting from “one-way sales” to “two-way co-research and exchange of rights and interests”; upgrading from “single-product transactions” to “comprehensive output of technology platforms, complete solutions, and industrial systems”; and transitioning from “product licensing” to “joint development of multiple early-stage pipelines leveraging proprietary innovative technology platforms.”

The evolution of the relationship between CSPC and AstraZeneca is almost a textbook case of this evolutionary process. From selling a single molecule（2024）, to selling AI platforms（2025）, to selling blockbuster GLP-1 assets(January 2026), to the siRNA platform for sale(July 2026), and then to establishing joint-venture factories(August 2026)—Deepening cooperation step by step, moving from "transactions" to "binding," and from "buying and selling" to "symbiosis."

Third, MNCs are “early-binding” Chinese innovation.

A notable trend is that MNCs are no longer satisfied with acquiring mature assets already in late-stage clinical development. They are beginning to extend their reach into earlier stages—preclinical, and even target discovery phases.

CSPC and AstraZeneca's Fourth Collaboration(siRNA Platform)This is a typical example: both parties will jointly discover and develop preclinical candidate drugs with therapeutic potential targeting two specific targets. This means that the two companies have already come together even before the molecules have taken shape. What multinational corporations (MNCs) are heavily investing in is no longer the rights to a single molecule, but rather the “reusable technological capabilities” of Chinese pharmaceutical companies.

This “early binding” strategy allows multinational corporations (MNCs) to secure high-quality assets ahead of time in the fiercely competitive global race for innovative drugs, while enabling Chinese pharmaceutical companies to leverage MNCs’ global clinical development and commercialization capabilities to unlock greater value from their technology platforms.

Finally, China is becoming the global pharmaceutical “manufacturing hub.”

Another significance of the joint venture lies in manufacturing and production. AstraZeneca will establish a biologics manufacturing base in Shijiazhuang, targeting the global market, reflecting multinational pharmaceutical companies' reevaluation of China's manufacturing capabilities.

In the past, China’s role in the global pharmaceutical industry chain was largely that of an “active pharmaceutical ingredient (API) production base” or a “contract manufacturing organization for finished dosage forms.” This time, however, CSPC is exporting AI-driven GMP manufacturing and operational capabilities—a form of intelligent, digitalized advanced manufacturing. In its announcement, CSPC Pharmaceutical Group Limited stated that this collaboration marks a further extension of its internationalization strategy, evolving from “exporting products and technologies” to “exporting production systems and supply chain capabilities.”

Against the backdrop of global pharmaceutical companies continuously optimizing their R&D, manufacturing, and supply chain layouts, high-quality, efficient, and sustainable production and supply capabilities are increasingly becoming a core competitive advantage in the global innovative drug industry chain. China’s competitiveness in this segment is shifting from a “cost advantage” to a “technological advantage.”

TONACEA

An Endless Upgrade

The joint venture signing on August 5 will not be the end of the story between CSPC and AstraZeneca.

From the initial handshake in October 2024 to the establishment of a joint-venture manufacturing plant in August 2026, the relationship between the two companies has transformed from “transactional counterparts” to “strategic partners” in less than two years. Such speed and depth of transformation are rare in the history of international collaborations within China’s pharmaceutical industry.

Behind this lies CSPC’s sustained investment in its innovation-driven transformation. The company has established eight innovative technology platforms covering cutting-edge areas such as small molecules, antibodies, antibody-drug conjugates (ADCs), and small interfering RNA (siRNA). Its siRNA pipeline currently comprises approximately 10 candidates in development, with the most advanced candidate having progressed to Phase III clinical trials. These technological capabilities form the underlying rationale for AstraZeneca’s continued increased investment in CSPC.

This reflects AstraZeneca’s long-term commitment to the Chinese market: a RMB 100 billion investment by 2030, with a full value chain layout spanning R&D, manufacturing, and commercialization. The joint venture is merely the manifestation of this commitment on the manufacturing front.

More importantly, this reflects the systemic upgrading underway across China’s entire pharmaceutical industry. Collaborations between Chinese innovative drug developers and multinational corporations (MNCs) are entering a new phase characterized by “early-stage binding, risk-sharing, and value co-creation.” Cooperation models are shifting from one-way sales to bidirectional joint R&D; value delivery is evolving from single-product transactions to platform-based outputs; and regional strategies are transitioning from reliance on a single market to diversified global expansion.

The Story of CSPC and AstraZeneca: A Tale of Escalating Trust, and of China’s Pharmaceutical Industry Moving from “Following” to “Running Side by Side”

Yet the story is far from over. What products will the joint venture produce in the future? In what forms will the fifth and sixth collaborations between the two parties emerge? To what extent will the collaboration model between Chinese innovative drugs and multinational corporations (MNCs) continue to evolve?

The answers to these questions are being written. The factory in Shijiazhuang has just driven its first pile.

References:

CSPC and AstraZeneca Sign Joint Venture Agreement to Establish a Joint Venture Company, Further Deepening Strategic Cooperation; CSPC

AZ's Four Bets on CSPC: MNCs Rush to Secure Early-Stage R&D Assets in China; Tongxieyi

This tweet is intended for knowledge dissemination. If you have any questions regarding copyright or other matters, please contact Medical Overview within 30 days of the publication of this article.

Original content is prohibited from being reposted to other platforms without authorization.

Previous Issues

“The Making of a ‘Tiny Vaccine’” | Pharmaceutical Company Pipeline Inventory

Immunology for Everyone| Immunology for Everyone (Audio Version)

Interpretation of Review Articles | Brief Literature Review | Medical Science Popularization|Frontiers in Medicine Notes

PROTAC Technology| Antibody Drugs| Antibody-Drug Conjugate - ADC

Nucleic Acid Vaccines | CAR Technology| Chemical Biology